Lipoprotein-associated phospholipase A2 predicted cardiovascular disease in obstructive sleep apnea syndrome

Normolipidic diet containing deep-fried saturated and unsaturated fatty acids rich edible oils promotes metabolic dysregulation and inflammatory microenvironment in Wistar rats

Deleterious health impacts of high dietary intake of deep-fried edible oils have been reported however, their health impacts at normal dietary levels are yet to be evaluated. This study investigated the influence of prolonged consumption of thermally oxidised long-chain saturated and unsaturated edible oils on metabolic dysregulation and inflammation. The thermally oxidised oils used in the study possess higher p-anisidine values and free fatty acid contents compared to unoxidised oils. Fourier transform infrared spectroscopy and fatty acid methyl ester analysis confirmed the presence of free fatty acids, hydroperoxides, and aldehydes, formed during thermal oxidation. The study analysed the effects of dietary intake of 5% sunflower oil, palm oil, and their thermally-oxidised forms in male Wistar rats for six months. Unoxidised and thermally oxidised palm oil-fed animals experienced metabolic syndrome with obesity-associated inflammatory changes. However, sunflower oil-fed animals exhibited increased inflammation, as evidenced by enhanced C-reactive protein, IL-6, and lipoprotein-associated phospholipase A2 activity and hepatosteatosis condition. This study indicates that prolonged consumption of thermally oxidised oil leads to the dysregulation of carbohydrate and lipid metabolism andpromotes inflammatory microenvironment in Wistar rats that may contribute to metabolic syndrome associated with obesity and hepatic steatosis.

Lipoprotein-Associated Phospholipase A2 Correlates with Reduced Left Ventricle Ejection Fraction in Hemodialysis Patients

OBJECTIVE

Reduced left ventricular ejection fraction (LVEF) is common in hemodialysis (HD) patients. Lipoprotein-associated phospholipase A2 (Lp-PLA2) is considered an important determinant of cardiovascular events. The aim of the study was to evaluate the relationship between Lp-PLA2 and LVEF in HD patients.

METHODS

Fifty-seven HD patients with coronary heart disease were enrolled. Predialysis and postdialysis venous whole blood samples were collected. The patients were divided into preserved and reduced LVEF groups. The relationship between Lp-PLA2 and LVEF was assessed.

RESULTS

A significant difference in C-reactive protein (CRP) and Lp-PLA2 was observed, with higher levels noted in patients with reduced LVEF (P ≤ .001). Both Lp-PLA2 and CRP were negatively correlated with LVEF in the HD patients. Only Lp-PLA2 remained associated with LVEF in multiple regression analysis.

CONCLUSION

Lipoprotein-associated phospholipase A2 levels are associated with LVEF and could potentially be used to evaluate chronic heart failure with reduced LVEF in HD patients for risk stratification management.

A Wearable Functional Near-Infrared Spectroscopy (fNIRS) System for Obstructive Sleep Apnea Assessment

Obstructive sleep apnea (OSA), one of the most common sleep-related breathing disorders, contributes as a potentially life-threatening disease. In this paper, a wearable functional near-infrared spectroscopy (fNIRS) system for OSA monitoring is proposed. As a non-invasive system that can monitor oxygenation and cerebral hemodynamics, the proposed system is dedicated to mapping the pathogenic characteristics of OSA to dynamic changes in blood oxygen concentration and to constructing an automatic approach for assessing OSA. An algorithm including feature extraction, feature selection, and classification is proposed to signals. Permutation entropy(PE), for quantitative measuring the complexity of time series, is firstly involved to characterize the features of the physiological signals. Subsequently, the principal component analysis (PCA) for feature dimensionality reduction and support vector machine (SVM) algorithm for OSA classification are applied. The proposed method has been validated on a dataset that collected by the wearable system. It includes 40 subjects and composes of normal, and various severity cessation of breathing (e.g., mild, moderate, and severe). Experimental results exhibit that the proposed system can effectively distinguish OSA and non-OSA subjects, with an accuracy of 91.89%. The proposed system is expected to pave the novel perspective for OSA assessment in terms of cerebral hemodynamics.

Increased sedentary time and decreased physical activity increases lipoprotein associated phospholipase A2 in obese individuals

BACKGROUND AND AIMS

Lipoprotein-associated Phospholipase A₂ (Lp-PLA₂) is a protein produced by inflammatory cells in circulation and is associated with cardiovascular disease (CVD) risk. Physical activity (PA) is known to reduce inflammation and risk for CVD. However, Lp-PLA₂ has yet to be examined in relation to PA and sedentary time. The purpose of this study was to determine if PA and sedentary time impacts Lp-PLA₂ mass. A total of 25 subjects with an average BMI of 30.6 ± 5.7 were included in the data analysis.

METHODS AND RESULTS

Data collected included anthropometric data, Lp-PLA₂ mass, peak oxygen uptake (VO₂peak), resting heart rate and blood pressure, obstructive sleep apnea (OSA) risk, and assessment of PA using an accelerometer. Sedentary minutes per day was positively associated with Lp-PLA₂ (r = 0.41, P < 0.05). Light intensity PA was negatively associated (r = -0.51. P = 0.01) with Lp-PLA₂. When subjects were divided into 2-quantiles by Lp-PLA₂, the group with the higher Lp-PLA₂ mass accumulated more sedentary time per day (P < 0.001) and less light intensity PA per day (P = 0.001). OSA risk and Lp-PLA₂ showed no relationship. Sedentary behavior was higher, and light intensity PA was lower in subjects with hiLp-PLA₂ mass. No difference was seen in moderate-to-vigorous intensity PA or steps per day.

CONCLUSIONS

This suggests that, total PA habits, including time spent sedentary and lower intensity PA, impacts the levels of Lp-PLA₂, an important inflammatory marker and marker of CVD risk.

Correlation between Serum LP-PLA2 and sST2 Levels and the Condition of Patients with Acute Heart Failure and Their Prognostic Value

Acute heart failure (AHF) occurs mostly in the elderly, which is a syndrome that occurs in the later stages of the development of cardiovascular disease. Due to the sharp decline in the patient's heart function, the patient has a high mortality rate and a poor prognosis, which seriously threaten the life safety of the elderly. Therefore, early diagnosis of AHF and timely treatment are extremely important. Lipoprotein-associated phospholipase A2 (LP-PLA2) is a newly discovered cardiovascular-specific inflammatory marker, which is closely related to the formation and progression of atherosclerotic plaque and the occurrence and development of coronary heart disease. Soluble growth stimulation expression gene 2 (sST2) protein is a protein produced under the induction of mechanical stress in cardiomyocytes. It can act as a decoy receptor to mediate the interleukin-33 (IL-33)/ST2 signaling pathway to bind to IL-33, thereby reducing the myocardial protective effect and leading to myocardial remodeling. The purpose of this study was to explore the serum LP-PLA2 and sST2 levels in AHF patients and to analyze their correlation with the disease and their prognostic value. The results showed that the levels of serum LP-PLA2 and sST2 were increased in AHF patients, and the levels of serum LP-PLA2 and sST2 in patients with adverse prognostic events were higher than those in patients without adverse prognostic events. The levels of serum LP-PLA2 and sST2 are closely related to the degree of patients' illness, among which the combined prediction of AHF patients with LP-PLA2 and sST2 has the highest value, which is worthy of promotion.

Relationship between Plasma Lipoprotein-Associated Phospholipase A2 Concentrations and Apolipoprotein in Stable Coronary Artery Disease Patients

Background

Increasing evidence states that the plasma lipoprotein-associated phospholipase A2 (Lp-PLA2) levels and apolipoprotein particles are regarded as the risk maker for cardiovascular heart disease. Nevertheless, the issue about whether Lp-PLA2 is associated with apolipoprotein particles in individuals who have been diagnosed as stable coronary artery disease (CAD) remains largely unexplored.

Method

All 569 participants engaged in this research, who never took lipid-lowering drugs, had been divided into groups by the coronary angiography (CAG), namely, stable CAD: n = 291; non-CAD: n = 278. The results concerning Lp-PLA2 levels were calculated by Elisa Kit, while apolipoprotein particles were measured by the department of laboratory.

Results

The plasma concentration of Lp-PLA2 was remarkably higher in stable CAD group than the non-CAD group (136.0 ± 60.5 ng/mL vs. 113.2 ± 65.6 ng/mL, P < 0.001). Pearson correlation analyses explained the plasma Lp-PLA2 concentration was correlated with apoB (r = 0.390, P < 0.001) and apoB/apoA1 (r = 0.450, P < 0.001), not associated with apoA1 (r = −0.099, P = 0.101). Conversely, the association remains unobserved among non-CAD patients except apoA1. Moreover, multiple linear regression revealed the relations between Lp-PLA2 concentrations and apoB (β = 0.390, P < 0.001), as well as apoB/apoA1 (β = 0.450, P < 0.001), but not apoA1 (β = −0.099, P = 0.121). After adjustment for several risk factors regarding CAD, like hypertension, gender, smoking, age, and diabetes mellitus, there had still been positive associations between the Lp-PLA2 concentration and apoB (β = 0.364, P < 0.001), as well as apoB/apoA1 (β = 0.390, P < 0.001).

Conclusion

The plasma levels of Lp-PLA2 provide positively a key link with apoB, apoB/apoA-1 among stable CAD, denoting the communication between Lp-PLA2 and apolipoprotein particles in the state of CAD.